Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Initial data encouraging for ilixadencel
July 2019
SHARING OPTIONS:

STOCKHOLM—Immunicum AB (publ) recently shared positive top-line results from its Phase 1/2 clinical trial, which evaluated the safety and tolerability of ilixadencel in combination with tyrosine kinase inhibitors in six patients with gastrointestinal stromal tumors (GIST). Ilixadencel demonstrated a favorable safety profile with no fatal treatment-related adverse events and no autoimmunity. The compound also showed signs of clinical benefit, with two patients presenting with a partial response to treatment in which tumor growth stopped and partially regressed for three months and six months, respectively.
 
“As a disease with limited therapeutic options, it is a considerable achievement to see partial response in two out of six advanced-stage GIST patients as the disease at that point has developed resistance to standard of care treatment with TKIs,” commented Dr. Robert Bränström, principal investigator and associate professor at Karolinska University Hospital.

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2019 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.